Gemcitabine plus cisplatin for the treatment of metastatic breast cancer

Clin Breast Cancer. 2002 May:3 Suppl 1:24-9. doi: 10.3816/cbc.2002.s.006.

Abstract

The combination of gemcitabine and cisplatin has proven effective as first-line chemotherapy for patients with breast cancer, inducing a response rate of 80% in one phase II study. Five additional studies in intensively pretreated breast cancer patients demonstrated a median response rate of 43% (range, 26%-50%). The toxicity profile was moderate, with thrombocytopenia and neutropenia as the main side effects. The gemcitabine/ cisplatin combination, therefore, offers a tolerable and effective treatment option, particularly for patients whose disease progressed after treatment with anthracyclines and/or taxanes.

Publication types

  • Review

MeSH terms

  • Anthracyclines
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Bridged-Ring Compounds
  • Cisplatin / administration & dosage
  • Clinical Trials, Phase II as Topic
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Female
  • Gemcitabine
  • Humans
  • Neoplasm Metastasis
  • Taxoids*
  • Trastuzumab
  • Treatment Failure
  • Treatment Outcome

Substances

  • Anthracyclines
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bridged-Ring Compounds
  • Taxoids
  • Deoxycytidine
  • taxane
  • Trastuzumab
  • Cisplatin
  • Gemcitabine